Jean-Sébastien Louis1, Jacques Felblinger1,2, Olivier Huttin3, and Marine Beaumont1,2
1IADI, Inserm U1254, Université de Lorraine, Nancy, France, 2CIC-IT, Inserm 1433, Université de Lorraine and CHRU Nancy, Nancy, France, 3Pôle cardiologie, CHRU Nancy, Nancy, France
Synopsis
Arterial Input Function (AIF) is fundamental for quantitative perfusion
analysis. However, AIF peak is underestimated when using common perfusion
sequence such SR-turboFLASH due to signal saturation effect. This leads to
biased perfusion parameters estimation. Accurate AIF sampling requires specific
sequence or protocol imaging not widely available. We proposed a solution to
correct AIF peak retrospectively from standard perfusion data. We evaluated the
proposed algorithm in simulation on more than 90000 different AIF sampling
scenarios. Eventually, we tested our algorithm on clinical data and compared
the population AIF estimated from our solution to literature population AIF.
Introduction
Quantitative perfusion analysis is very promising for diffuse fibrosis
diagnostic especially in cardiac MRI[1]. Arterial
Input Function (AIF) stands as a crucial step into quantitative perfusion study [2]. The
use of classical perfusion sequences such SR-TurboFLASH is met with signal
saturation when the contrast agent concentration ([CA]) is high[3]. This
phenomenon yields to an inaccurate measurement of the blood pool signal where
the [CA] is the highest and eventually yields to an underestimation of the AIF
peak. In fine, this leads to biased perfusion parameters estimation[4].
Adapted acquisition sequence such dual sequence [5] or adapted
injection protocol such dual bolus [6] have been
proposed to ensure a proper sampling of the AIF. Although these solutions are
still discussed they and require imaging sequences/protocols not always
available or manageable in all institutions. The goal of this work is to
propose a solution to correct retrospectively the underestimation of the AIF
peak when using common perfusion sequence which would enable quantitative
perfusion analysis.Methods
Framework:
The algorithm
framework is described in figure 1 and was developed in Matlab (The MathWorks,
Natick, MA, USA). The first step consists in oversampling the signal to time AIF
curve in order to homogenize data sampling to a temporal resolution equals to
0.5s. The second step consists in signal to CA concentration conversion using
the SR-turboFLASH signal equation. The third step consists in thresholding the
AIF values polluted by apparent saturation effect. The fourth step is a linear
regression of wash-in and wash-out part of the truncated AIF. The synthetic
peak is estimated as the intersection between the two generated lines. The last
step consisted in the reconstruction of two synthetic AIF both using the linear
approximation wash-in but with two wash-out estimation method. The first one
uses a combination between the linear approximation for CA concentration higher
than the threshold and the experimental data for CA concentration below the
threshold. The second one is a biexponential fitting of the previous one.
Simulation
validation:
We
tested the framework algorithm generating the first form of synthetic AIF on
several types of simulated AIF based on the Parker model[7] in different
condition of thresholding, temporal resolution and noise level. 51 AIF with
different peak values (6.1mM to 13.1mM) have been generated and truncated
according to 51 saturation threshold values (2mM to 4,5mM). We tested the 306
combinations of truncated AIF in 36 combinations of 6 different temporal
resolution (0.5s to 1.5s) and 6 different noise level (0mM to 0,15mM). We
represented the error estimation in a 341x341 matrix corresponding to the 36
matrices of 51 saturation threshold by 51 peak value of temporal resolution.
Clinical
validation:
The
algorithm has been tested on 16 manually measured AIF from 16 patients
extracted from the STAMP study (NCT02879825)[8]. AIF was
acquired with an SR-TurboFLASH (TS=95ms, TR/TE=4/0.97ms, GRAPPA=2-3, FA=10°).
Saturation threshold value of 3mM was used. It was determined by a previous
work which consisted in measurements of signal values from the same SR-Turbo
FLASH sequence parameters in function of known CA concentration.
A
population AIF was calculated as the average of the measured AIF aligned on the
end of the baseline. We compared this population AIF to the one reported in [7].Results
Simulation
validation:
Peak estimation
errors are presented in figure 2. Matrix representation exhibits banding
patterns. We observed an overestimation of the peak (i.e.>9%) when the
actual peak had low values (<8mM) and the saturation threshold was high
(>3.65mM). Inversely, we observed an underestimation of the peak
(i.e.<-11.6%) when saturation threshold was lower than 3.3mM and the actual
peak value was high (>9.9mM). We observed that a degraded temporal
resolution accentuates the peak underestimation. Noise level did not have a
clear impact on the observed matrix patterns. However, high level of noise tended
to smooth the banding effect which may underly a lower precision of peak
estimation.
Clinical
validation:
The sixteen corrected
AIF are represented in figure 3. All corrected AIF apart from figure3.o and
figure3.p had consistent shape with a mean estimated peak equals to 8.2±1.8mM.
Population AIF is represented in figure 4 and is very similar to literature
such Parker model’s AIF. Average population AIF peak value is equal to
7.03±1.8mM slightly higher than 6.1 mM of the parker’s model AIF.Discussion & conclusion
Results from simulation showed that our algorithm improves the estimation
of the AIF peak. Saturation threshold has to be selected in function of the
expected maximum concentration. Results from clinical data showed the
robustness of the algorithm as well as its ability to reconstruct consistent
AIF in comparison to population-based AIF of the literature. A direct
comparison between our solution and dual sequence or dual bolus solution needs
to be conducted. This solution could enable the retrospective quantitative
perfusion analysis from common perfusion sequences such SR-turboFLASH. Furthermore,
our solution led to an increase in the accuracy of the perfusion/DCE parameters
estimates (results not shown).Acknowledgements
No acknowledgement found.References
[1] A.
A. Robinson, M. Salerno, and C. M. Kramer, “Contemporary Issues in Quantitative
Myocardial Perfusion CMR Imaging,” Curr Cardiovasc Imaging Rep, vol. 12,
no. 3, p. 9, Feb. 2019, doi: 10.1007/s12410-019-9484-6.
[2] P. Slomka, Y. Xu, D. Berman, and G.
Germano, “Quantitative Analysis of Perfusion Studies: Strengths and Pitfalls,” J
Nucl Cardiol, vol. 19, no. 2, pp. 338–346, Apr. 2012, doi:
10.1007/s12350-011-9509-2.
[3] T. P. L. Roberts, “Physiologic
measurements by contrast-enhanced MR imaging: Expectations and limitations,” Journal
of Magnetic Resonance Imaging, vol. 7, no. 1, pp. 82–90, 1997, doi:
10.1002/jmri.1880070112.
[4] P. Kellman, A. H. Aletras, L. Hsu, E.
R. McVeigh, and A. E. Arai, “T2∗ Measurement During First-Pass
Contrast-Enhanced Cardiac Perfusion Imaging,” Magn Reson Med, vol. 56,
no. 5, pp. 1132–1134, Nov. 2006, doi: 10.1002/mrm.21061.
[5] P. D. Gatehouse, A. G. Elkington, N.
A. Ablitt, G.-Z. Yang, D. J. Pennell, and D. N. Firmin, “Accurate assessment of
the arterial input function during high-dose myocardial perfusion
cardiovascular magnetic resonance,” Journal of Magnetic Resonance Imaging,
vol. 20, no. 1, pp. 39–45, Jul. 2004, doi: 10.1002/jmri.20054.
[6] T. F. Christian et al.,
“Absolute Myocardial Perfusion in Canines Measured by Using Dual-Bolus
First-Pass MR Imaging,” Radiology, vol. 232, no. 3, pp. 677–684, Sep.
2004, doi: 10.1148/radiol.2323030573.
[7] G. J. M. Parker et al.,
“Experimentally-derived functional form for a population-averaged
high-temporal-resolution arterial input function for dynamic contrast-enhanced
MRI,” Magnetic Resonance in Medicine, vol. 56, no. 5, pp. 993–1000, Nov.
2006, doi: 10.1002/mrm.21066.
[8] “Myocardial Characterization of
Arrhythmogenic Mitral Valve Prolapse (STAMP: STretch and Myocardial
Characterization in Arrhythmogenic Mitral Valve Prolapse).” https://clinicaltrials.gov/ct2/show/NCT02879825.